Related Experiment Video
Updated: May 4, 2026

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes
Published on: May 14, 2012
The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies
Zachary S Scheiner1, Sohel Talib, Ellen G Feigal
1From the California Institute for Regenerative Medicine, San Francisco, California 94107.
Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune-privileged. However, there are reasons to question this assumption, including recent studies that have tested iPSC immunogenicity in various ways with conflicting results. Understanding the risk of an immune response and developing strategies to minimize it will be important steps before clinical testing. Here, we review the evidence for autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.
Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell therapies for a wide range of diseases and injuries. It is generally assumed that cells derived from autologous iPSCs will be immune-privileged. However, there are reasons to question this assumption, including recent studies that have tested iPSC immunogenicity in various ways with conflicting results. Understanding the risk of an immune response and developing strategies to minimize it will be important steps before clinical testing. Here, we review the evidence for autologous iPSC immunogenicity, its potential causes, and approaches for assessment and mitigation.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
iPS Cell Differentiation
Stem Cell Culture
EPS and iPS Cells in Disease Research

